| This is a promotional email from Gilead intended for healthcare professionals only. A link to the prescribing information and adverse events reporting can be found at the end of this email.
|
|
|
|
Gilead-sponsored meeting:
Managing COVID-19: Practical perspectives on a multifaceted treatment approach
|
|
Join us on 8 March 2022,
17:00-17:45 GMT / 18:00-18:45 CET
|
|
|
|
| Join us to hear our experts discuss how to manage patients with COVID‑19 at different points in the disease spectrum and how they address clinical challenges. The faculty will share insights from their own clinical practice and discuss how emerging data can help inform treatment decisions and future management strategies.
|
|
 |
| Dr David Wohl |
| Professor of Medicine, Institute for Global Health and Infectious Diseases University of North Carolina School of Medicine, Chapel Hill, NC, USA |
|
 |
| Prof. Elizabeth Sapey |
| Chair of Acute and Respiratory Medicine, Director of the Institute of Inflammation and Ageing, Director of PIONEER, the Health and Research, Data Hub for acute care, Consultant in Acute and Respiratory Medicine, Birmingham, UK |
|
|
|
|
|
| We look forward to seeing you there!
|
|
February 2022
IHQ-RDV-0219 |
|
|
|
This meeting will include materials and discussions of Gilead products.
Full prescribing information for VEKLURY®▼ (remdesivir) is available here: https://www.emcpi.com/pi/ni/423.
For HCPs in England, Scotland & Wales please follow this link: https://www.emcpi.com/pi/38228.
▼This medicinal product is currently subject to additional monitoring, as indicated by the presence of the inverted black triangle.
Remdesivir was granted a conditional marketing authorisation in Europe and GB
|
|
Adverse Events should be reported:
For the UK, reporting forms and information can be found at https://coronavirus-yellowcard.mhra.gov.uk/ or via the Yellow Card app (download from the Apple App Store or Google Play Store). For Ireland, reporting forms and information can be found at www.hpra.ie and can be reported to HPRA on +353 1 6764971.
All adverse events should also be reported to Gilead to safety_FC@gilead.com or +44 (0) 1223 897500 and to your national reporting system.
|
|
| © 2022 Gilead Sciences. All rights reserved.
|
|
